Q4 2018 EPS Estimates for Eli Lilly and Co (LLY) Lifted by Analyst
Eli Lilly and Co (NYSE:LLY) – Analysts at Leerink Swann increased their Q4 2018 earnings per share estimates for shares of Eli Lilly and in a report released on Thursday. Leerink Swann analyst S. Fernandez now anticipates that the company will earn $1.37 per share for the quarter, up from their previous estimate of $1.14. Leerink Swann currently has a “Market Perform” rating and a $93.00 price target on the stock. Leerink Swann also issued estimates for Eli Lilly and’s FY2022 earnings at $6.41 EPS.
Several other research firms have also issued reports on LLY. BMO Capital Markets set a $73.00 price target on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Credit Suisse Group downgraded shares of Eli Lilly and from an “outperform” rating to a “neutral” rating and increased their price target for the stock from $84.23 to $88.00 in a research note on Tuesday, October 10th. Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and increased their price target for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the company a “buy” rating in a research note on Tuesday, January 16th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $105.00 target price on shares of Eli Lilly and in a research note on Friday, October 13th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $92.02.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share for the quarter, topping the consensus estimate of $1.08 by $0.06. The firm had revenue of $6.16 billion for the quarter, compared to analysts’ expectations of $5.93 billion. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share.
A number of hedge funds have recently modified their holdings of LLY. Vanguard Group Inc. increased its holdings in shares of Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares during the period. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2.1% during the 2nd quarter. BlackRock Inc. now owns 63,583,747 shares of the company’s stock worth $5,232,942,000 after acquiring an additional 1,323,259 shares during the last quarter. Janus Henderson Group PLC boosted its stake in shares of Eli Lilly and by 16.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock worth $928,719,000 after acquiring an additional 1,503,918 shares during the last quarter. Dodge & Cox boosted its stake in shares of Eli Lilly and by 22,094.9% during the 2nd quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after acquiring an additional 5,964,955 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its stake in shares of Eli Lilly and by 91.1% during the 2nd quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after acquiring an additional 2,714,505 shares during the last quarter. Institutional investors own 76.45% of the company’s stock.
In related news, SVP Susan Mahony sold 36,585 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total value of $3,152,895.30. Following the sale, the senior vice president now owns 54,885 shares in the company, valued at $4,729,989.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $81.09, for a total transaction of $72,981.00. Following the completion of the sale, the insider now owns 4,130 shares in the company, valued at approximately $334,901.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 261,613 shares of company stock worth $22,894,997. Corporate insiders own 0.20% of the company’s stock.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This is a boost from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.89%. Eli Lilly and’s dividend payout ratio is presently -1,040.00%.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.